BioWorld

June 23, 2004

Vertex, Merck Form Potential $384M Cancer Deal For VX-680

In a deal potentially worth $384 million for Vertex Pharmaceuticals Inc., the company entered a global collaboration with Merck & Co. Inc. to develop and commercialize the former's lead aurora kinase inhibitor, VX-680. (BioWorld Today) Read More

Merix, Kirin Collaborating For Personalized Vaccine Products

CuraGen, Seattle Genetics Form Cancer Deal Worth Up To $32M

Momenta's Stock Closes Up After IPO Brings In $34.7M

Taste Technology Firm Senomyx Goes Public With $36M Offering

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...